SNDX NASDAQ
Credit Risk of going bust: higher than 67% of companies Debt: 33.3% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.61 (down 95%), Syndax Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $589.4M against a stock market value of $1.18B.
Distance to default 3.69 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $294.1M (short-term plus half of long-term), stock volatility 52.2%; Altman Z'' -3.36. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
New York City, NY 10017
US
Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Metzger Michael A | M-Exempt | 32,375 | $6.38 | 2026-07-08 |
| Metzger Michael A | S-Sale | 32,375 | $24.24 | 2026-07-08 |
| Metzger Michael A | M-Exempt | 32,375 | $6.38 | 2026-07-08 |
| Botwood Nicholas A.J | M-Exempt | 31,235 | $13.82 | 2026-06-12 |
| Botwood Nicholas A.J | S-Sale | 31,235 | $18.14 | 2026-06-12 |